4.6 Review

Nanoparticles for imaging and treatment of metastatic breast cancer

Journal

EXPERT OPINION ON DRUG DELIVERY
Volume 14, Issue 1, Pages 123-136

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1080/17425247.2016.1208650

Keywords

Nanoparticles; breast cancer; metastasis; imaging; drug delivery; cancer stem cells; immunotherapy

Funding

  1. NIH [R01CA161953]
  2. Kyocera endowment
  3. NIH Ruth L. Kirschstein T32 Fellowship [T32CA138312]
  4. NATIONAL CANCER INSTITUTE [R01CA161953, T32CA138312] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Introduction: Metastatic breast cancer is one of the most devastating cancers that have no cure. Many therapeutic and diagnostic strategies have been extensively studied in the past decade. Among these strategies, cancer nanotechnology has emerged as a promising strategy in preclinical studies by enabling early identification of primary tumors and metastases, and by effective killing of cancer cells. Areas covered: This review covers the recent progress made in targeting and imaging of metastatic breast cancer with nanoparticles, and treatment using nanoparticle-enabled chemo-, gene, photothermal- and radio-therapies. This review also discusses recent developments of nanoparticle-enabled stem cell therapy and immunotherapy. Expert opinion: Nanotechnology is expected to play important roles in modern therapy for cancers, including metastatic breast cancer. Nanoparticles are able to target and visualize metastasis in various organs, and deliver therapeutic agents. Through targeting cancer stem cells, nanoparticles are able to treat resistant tumors with minimal toxicity to healthy tissues/organs. Nanoparticles are also able to activate immune cells to eliminate tumors. Owing to their multifunctional, controllable and trackable features, nanotechnology-based imaging and therapy could be a highly potent approach for future cancer research and treatment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available